Another study evaluating myostatin inhibition in mild SMA model mice (generated by treatment with a suboptimal dose of an SMN2-splicing modifier) demonstrated efficacy in late disease stages [268]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.